ERBB2 and breast cancer: Recently, an immunophenotypic profiling of circulating and intratumor immune cells determined that compared to HER2-cases, patients with HER2-overexpressing locally advanced BC show a more limited tumor-related immune suppression (Muraro et al., 2011).